Profound Medical Corp
PROF
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
170.2% downsideOvervalued by 170.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $206.07 Million |
|---|---|
| Enterprise Value | $160.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.43 |
| Beta | 0.73 |
| Outstanding Shares | 36,297,684 |
Return
| Return on Equity | 127.37% |
|---|---|
| Return on Assets | 103.04% |
| Return on Invested Capital | -49.16% |
Valuation & Multiples
| P/E Ratio | -5.98 |
|---|---|
| PEG | 3.62 |
| Price to Sales | - |
| Price to Book Ratio | 6.79 |
| Enterprise Value to Revenue | 19.5 |
| Enterprise Value to EBIT | -5.21 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9096▲ 190.96% |
|---|---|
| Total Calls | 33,200▲ Infinity% |
| Total Puts | 63,400▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 54.04%▲ 0.70% |
|---|---|
| Total Invested | $105.59M▼ 16.40% |
| Investors Holding | 61▼ 2.00% |
ESG Score
No data
About Profound Medical Corp
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO®, a technology that combines real-time MR...
Relevant Senate Committees
Controls taxation, which impacts corporate profitability, and entitlement spending (Medicare pricing), which is crucial for the reimbursement and adoption of medical devices.
Its subcommittees directly determine the funding for federal healthcare programs (VA, DoD), scientific research (NIH), and other initiatives that can impact the procurement and development of medical devices.
Directly regulates the FDA, which is responsible for the clearance and approval of Profound's medical devices (510(k) cleared, HDE approved). Also influences NIH funding for medical research.
Oversees intellectual property rights, which are critical for medical device companies to protect their innovations, and antitrust laws, which impact market competition and mergers.
Oversees the Department of Defense, which procures medical technologies for military healthcare, directly impacting potential revenue streams for medical device companies like Profound.
Directly oversees the Department of Veterans Affairs, whose funding decisions and procurement policies directly impact government healthcare contractors and medical device manufacturers like Profound.